FIELD: biotechnology.
SUBSTANCE: antibody molecule binding to programmed cell death protein ligand-1 (hereinafter – PD-L1) and lymphocyte activation genome 3 (hereinafter – LAG-3) are proposed. The antibody molecule contains a site of binding PD-L1 based on CDR and a site of binding LAG-3, which is located in loops AB and EF of CH3-domain of the antibody molecule. The invention also relates to nucleic acid encoding the antibody, an expression vector and a recombinant host cell, and a method for the production of the antibody. In addition, a pharmaceutical composition including the specified antibody is proposed.
EFFECT: antibody molecules, according to the present invention, can be used in the treatment of cancer.
36 cl, 16 dwg, 17 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY MOLECULES THAT BIND CD137 AND OX40 | 2019 |
|
RU2817602C2 |
| MOLECULES BINDING MESOTHELIN AND CD137 | 2019 |
|
RU2815066C2 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| VARIANTS OF FC-REGION WITH MODIFIED ABILITY TO BIND TO FCRN AND WITH PRESERVED ABILITY TO BIND WITH PROTEIN A | 2015 |
|
RU2727639C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| VERSIONS OF THE FC-DOMAIN WITH MODIFIED ABILITIES TO BIND TO FCRN | 2015 |
|
RU2730592C2 |
| PSEUDO-FAB BASED MULTISPECIFIC BINDING PROTEINS | 2019 |
|
RU2820254C2 |
| ANTIBODY AGAINST LAG-3 | 2017 |
|
RU2744866C2 |
| ANTIBODIES BINDING CTLA-4 AND APPLICATION THEREOF | 2018 |
|
RU2756100C1 |
| HUMAN ANTIBODIES BINDING TO ROR2 | 2018 |
|
RU2784586C2 |
